The Ontario Institute for Cancer Research (OICR) has made an investment in the development of a radiolabeled insulin probe for the early detection of breast cancer.
The recipient of the award is John Valliant, Ph.D., an associate professor at McMaster University in Hamilton, Ontario, who has developed a form of insulin that is labeled with the radioisotope technetium.
It can be injected into the bloodstream and used to track changes in insulin metabolism, helping to find and monitor tumors that currently are difficult to detect.
OICR will participate in efforts to commercialize the project by providing additional expertise and resources and by working collaboratively with McMaster University and Valliant.
Related Reading
BRCA carriers have higher risk of contralateral breast cancer, April 6, 2010
Breast cancer risk assessment starts with the right questions, March 23, 2010
Radiation exposure increases risk of breast cancer, March 4, 2010
Prophylactic mastectomy helpful in BRCA mutation carriers, March 3, 2010
Family history boosts contralateral breast cancer risk after radiotherapy, November 4, 2008
Copyright © 2010 AuntMinnie.com
